NDAORALTABLET
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Clinical Trials (1)
QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
Started Dec 2021
679 enrolled
Type 2 Diabetes Mellitus
Loss of Exclusivity
LOE Date
Jun 16, 2030
52 months away
Patent Expiry
Jun 16, 2030
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 6515117 | Oct 4, 2025Expired | SubstanceProduct | U-493 |
| 6515117*PED | Apr 4, 2026 | — | |
| 8501698 | Jun 20, 2027 | Product | U-493 |
| 8501698*PED | Dec 20, 2027 | — | |
| 8361972 | Mar 21, 2028 | U-493 |